Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR1459 in Adult Patients With NMOSD
NCT04670770Phase 2Completed
- Sponsor
- Reistone Biopharma
- Start
- Jan 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of edralbrutinib in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Reistone Biopharma. Primary endpoint: Evaluate the efficacy of SHR1459 in patients with relapsing NMOSDs at 52 weeks. Started Jan 2021; status: completed.
02
Drugs
edralbrutinib
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT04670770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04670770.